Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel in high-risk prostate cancer
jRCTs021180009Recruiting
- Start
- Sep 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of docetaxel and estramustine in prostate cancer (PCa). Primary endpoint: surgical CR rate. Started Sep 2015; status: recruiting.
02
Drugs
docetaxelestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs021180009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180009.